In conclusion, we have identified novel and recurrent heterozygous activating variants of the GCM2 gene and provided evidence that they are potential contributors to the pathogenesis of hyperparathyroidism and could be associated with parathyroid carcinoma. This evidence concerns the gene GCM2 and hyperparathyroidism.